Cost analyses of HIV treatment should be standardized and report cost drivers
AIDS
.
2021 Jul 1;35(8):1311-1312.
doi: 10.1097/QAD.0000000000002931.
Authors
Arielle Lasry
1
,
Madeleine Baker-Goering
Affiliation
1
US Centers for Disease Control and Prevention, Atlanta, GA, USA.
PMID:
34076618
PMCID:
PMC9341127
DOI:
10.1097/QAD.0000000000002931
No abstract available
Publication types
Comment
MeSH terms
Cost-Benefit Analysis
HIV Infections* / drug therapy
Humans
Grants and funding
CC999999/ImCDC/Intramural CDC HHS/United States